Navigation Links
Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
Date:9/10/2012

ROCKVILLE, Md., Sept. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 11 at 2:00 p.m. EDT, at The Waldorf=Astoria, Starlight South. Garr will discuss the company's opportunities and advancements in neural stem cell therapy and pharmaceuticals.  He will be providing an update on ongoing clinical trials, including the recently completed ALS Phase I, and an overview on future trials. To view the live webcast, visit Neuralstem's Investor Center at www.neuralstem.com , or: http://www.wsw.com/webcast/rrshq22/cur .

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Rodman & Renshaw Annual Healthcare Conference is being held at The Waldorf=Astoria in New York City, September 9-11. For more information, see: http://www.rodm.com/conferences?id=176 .

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information     

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
2. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
3. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
6. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
7. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
8. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
9. Survey Shows Physicians Divided as Presidential Election Nears
10. Elekta President and CEO Tomas Puusepp Pledges Support in Addressing Global Cancer Challenge at World Cancer Leaders Summit in Montreal
11. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):